SomnoMed Ltd makes inroads into US market

SomnoMed Ltd (ASX:SOM), the leaders in Continuous Open Airway Therapy (COAT) has received approval from the US Government to have its oral appliances reimbursed by the US Medicare insurance program.

The company also launched its SomnoDent Herbst Advanced Classic and Flex Oral appliances for the treatment of obstructive sleep apnoea in the US. SomnoMed reported that it sold 4,535 sleep apnoea devices in September 2014, a 25.2% increase over the same period last year. The company also noted that it is constructing a new manufacturing facility in Australia that will double its production capacity. Since its launch, it has sold over 200,000 of its patented SomnoDent sleep apnoea appliances. SomnoMed is a publicly traded company (ASX:SOM) founded in 2004 in Sydney, Australia. The North American office, located in Frisco, Texas was opened in 2006 thus introducing their leading device technology to patients in America.